Marker Therapeutics (NASDAQ:MRKR) Issues Earnings Results, Beats Expectations By $0.16 EPS

Marker Therapeutics (NASDAQ:MRKR) posted its quarterly earnings results on Friday. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.16, Zacks reports. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%.

Marker Therapeutics Stock Performance

NASDAQ MRKR traded up $0.03 during trading hours on Friday, reaching $1.14. The company’s stock had a trading volume of 45,559 shares, compared to its average volume of 164,618. The company’s 50-day moving average is $1.33 and its two-hundred day moving average is $1.43. Marker Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $2.46. The stock has a market cap of $19.00 million, a PE ratio of -1.87 and a beta of 1.50.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a research report on Wednesday, May 20th. Weiss Ratings lowered shares of Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Marker Therapeutics currently has an average rating of “Hold” and an average target price of $10.00.

Institutional Trading of Marker Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRKR. NewEdge Advisors LLC purchased a new position in Marker Therapeutics in the 4th quarter valued at about $222,000. Osaic Holdings Inc. grew its holdings in shares of Marker Therapeutics by 16.5% during the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after buying an additional 13,340 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Marker Therapeutics by 16.4% in the fourth quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock valued at $184,000 after buying an additional 17,400 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Marker Therapeutics by 35.3% in the fourth quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock valued at $194,000 after buying an additional 34,028 shares during the last quarter. Finally, XTX Topco Ltd lifted its stake in shares of Marker Therapeutics by 166.6% during the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after buying an additional 36,269 shares during the period. Hedge funds and other institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.